CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) has developed a proprietary extended release subcutaneous (SC) depot formulation (ETI-511) of the NSAID drug meloxicam. ETI-511 enables delivery of high concentrations of meloxicam to a localized area over an extended period of time and therefore provides a potential variety of new therapeutic applications for pain and inflammation indications such as Arthritis, localized trauma such as sports injuries and post-surgical analgesia / inflammation. The company is seeking development partners to commercialize ETI-511.
